Leptospirosis - Revision history

ClaireLewis at 17:29, 16 October 2019

2019-10-16T17:29:12Z

← Older revision		Revision as of 17:29, 16 October 2019
Line 12:		Line 12:
	==Clinical Features==		==Clinical Features==
	*Acute phase (lasts up to 1 week)		*Acute phase (lasts up to 1 week)
	**Mild illness to abrupt high fever, chills, intense headache, and severe ~~myalgias~~ (75-100% of patients)		**Mild illness to abrupt high [[fever]], chills, intense [[headache]], and severe [[myalgia]]s (75-100% of patients)
	*Conjunctival suffusion (redness without exudates) characteristic but not common		*Conjunctival suffusion ([[red eye\|redness]] without exudates) characteristic but not common
	*Meningitis, uveitis, transaminitis, hepatomegaly, proteinuria, hematuria		*[[Meningitis]], [[uveitis]], [[hepatitis\|transaminitis]], [[hepatomegaly]], [[proteinuria]], [[hematuria]]
	*Weil syndrome - severe manifestation with jaundice and renal failure, aseptic meningitis, pulmonary hemorrhage, ARDS, myocarditis, and rhabdomyolysis (52% Mortality)		*Weil syndrome - severe manifestation with [[jaundice]] and [[renal failure]], aseptic [[meningitis]], [[diffuse alveolar hemorrhage\|pulmonary hemorrhage]], [[ARDS]], [[myocarditis]], and [[rhabdomyolysis]] (52% Mortality)
	**10% of patients		**10% of patients
	**Caused by circulating antibodies		**Caused by circulating antibodies
Line 25:		Line 25:
	*Confirm by serology		*Confirm by serology
	*Culture		*Culture
	*Hypokalemia/Hyponatremia		*[[Hypokalemia]]/[[Hyponatremia]]
	*Thrombocytopenia		*[[Thrombocytopenia]]
	*~~Sterile~~ pyuria		*[[UA]] with sterile pyuria
	*Elevated CK		*Elevated CK
	*CSF with elevated wbcs and protein with normal glucose		*[[CSF]] with elevated wbcs and protein with normal glucose

	==Management<ref>http://www.moh.gov.my/images/gallery/Garispanduan/GL_Leptospirosis%202011.pdf Ministry of Health Malaysia 2011 Recommendations</ref>==		==Management<ref>http://www.moh.gov.my/images/gallery/Garispanduan/GL_Leptospirosis%202011.pdf Ministry of Health Malaysia 2011 Recommendations</ref>==
	*Penicillin G 100000U/ kg/ dose IV every 6 hours x 7days		*[[Penicillin G]] 100000U/ kg/ dose IV every 6 hours x 7days
	'''OR'''		'''OR'''
	*'''>8yrs:''' Doxycycline 4mg/kg/dose oral every 12 hours x 7 days		*'''>8yrs:''' [[Doxycycline]] 4mg/kg/dose oral every 12 hours x 7 days
	*'''<8yrs:''' [[Ampicillin]] 75-100mg/kg/dose oral every 6 hours x 7days		*'''<8yrs:''' [[Ampicillin]] 75-100mg/kg/dose oral every 6 hours x 7days
	*'''<8yrs:''' [[Amoxicillin]] 50mg/kg/dose oral 6- 8 hours x 7days		*'''<8yrs:''' [[Amoxicillin]] 50mg/kg/dose oral 6- 8 hours x 7days

Aganapathy: /* Clinical Features */

2018-01-28T09:02:50Z

Clinical Features

← Older revision		Revision as of 09:02, 28 January 2018
Line 15:		Line 15:
	*Conjunctival suffusion (redness without exudates) characteristic but not common		*Conjunctival suffusion (redness without exudates) characteristic but not common
	*Meningitis, uveitis, transaminitis, hepatomegaly, proteinuria, hematuria		*Meningitis, uveitis, transaminitis, hepatomegaly, proteinuria, hematuria
	*Weil syndrome - severe manifestation with jaundice and renal failure, pulmonary hemorrhage, ARDS, myocarditis, and rhabdomyolysis (52% Mortality)		*Weil syndrome - severe manifestation with jaundice and renal failure, aseptic meningitis, pulmonary hemorrhage, ARDS, myocarditis, and rhabdomyolysis (52% Mortality)
	**10% of patients		**10% of patients
	**Caused by circulating antibodies		**Caused by circulating antibodies

Rossdonaldson1: Text replacement - "[[Ceftriaxone]]" to "Ceftriaxone"

2017-03-12T06:25:32Z

Text replacement - "[[Ceftriaxone]]" to "Ceftriaxone"

← Older revision		Revision as of 06:25, 12 March 2017
Line 39:		Line 39:

	*Other alternatives:		*Other alternatives:
	**[[[[Ceftriaxone]]]], [[Cefotaxime]]<ref>Inada R, Ido Y, Hoki R. The etiology, mode of infection, and specific therapy of Weil's disease (spirochaetosis icterohaemorrhagica. J Exper Med. 1916;23:377-402.</ref>		**[[Ceftriaxone]], [[Cefotaxime]]<ref>Inada R, Ido Y, Hoki R. The etiology, mode of infection, and specific therapy of Weil's disease (spirochaetosis icterohaemorrhagica. J Exper Med. 1916;23:377-402.</ref>
	**''Prefer [[Azithromycin]] or [[Doxycycline]] if unable to distinguish from rickettsial infection.''		**''Prefer [[Azithromycin]] or [[Doxycycline]] if unable to distinguish from rickettsial infection.''

Ostermayer: Text replacement - "Ceftriaxone" to "Ceftriaxone"

2017-01-27T18:18:33Z

Text replacement - "Ceftriaxone" to "Ceftriaxone"

← Older revision		Revision as of 18:18, 27 January 2017
Line 39:		Line 39:

	*Other alternatives:		*Other alternatives:
	**[[Ceftriaxone]], [[Cefotaxime]]<ref>Inada R, Ido Y, Hoki R. The etiology, mode of infection, and specific therapy of Weil's disease (spirochaetosis icterohaemorrhagica. J Exper Med. 1916;23:377-402.</ref>		**[[[[Ceftriaxone]]]], [[Cefotaxime]]<ref>Inada R, Ido Y, Hoki R. The etiology, mode of infection, and specific therapy of Weil's disease (spirochaetosis icterohaemorrhagica. J Exper Med. 1916;23:377-402.</ref>
	**''Prefer [[Azithromycin]] or [[Doxycycline]] if unable to distinguish from rickettsial infection.''		**''Prefer [[Azithromycin]] or [[Doxycycline]] if unable to distinguish from rickettsial infection.''

Rossdonaldson1: Text replacement - " dx" to " diagnosis"

2016-07-31T06:46:24Z

Text replacement - " dx" to " diagnosis"

← Older revision		Revision as of 06:46, 31 July 2016
Line 6:		Line 6:
	*Also described following hiking, trekking, and following triathlon competitions<ref>CDC. Update: leptospirosis and unexplained acute febrile illness among athletes participating in triathlons--Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep. 1998;47(32):673-6</ref>		*Also described following hiking, trekking, and following triathlon competitions<ref>CDC. Update: leptospirosis and unexplained acute febrile illness among athletes participating in triathlons--Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep. 1998;47(32):673-6</ref>
	*Global estimate 1 million cases annually, 58,900 deaths<ref>Costa, F., Hagan, J.E., Calcagno, J., Kane, M., Torgerson, P., Martinez-Silveira, M.S., Stein, C., Abela-Ridder, B. and Ko, A.I. (2015) ‘Global morbidity and mortality of Leptospirosis: A systematic review’, PLOS Neglected Tropical Diseases, 9(9),</ref>		*Global estimate 1 million cases annually, 58,900 deaths<ref>Costa, F., Hagan, J.E., Calcagno, J., Kane, M., Torgerson, P., Martinez-Silveira, M.S., Stein, C., Abela-Ridder, B. and Ko, A.I. (2015) ‘Global morbidity and mortality of Leptospirosis: A systematic review’, PLOS Neglected Tropical Diseases, 9(9),</ref>
	*Uncommon in the US, although 50% of cases dx in Hawaii		*Uncommon in the US, although 50% of cases diagnosis in Hawaii

	[[File:Conjunctivalsuffusion.jpg\|thumb\|Conjunctival suffusion]]		[[File:Conjunctivalsuffusion.jpg\|thumb\|Conjunctival suffusion]]

Neil.m.young: Text replacement - "==Diagnostic Evaluation==" to "==Evaluation=="

2016-07-28T01:57:35Z

Text replacement - "==Diagnostic Evaluation==" to "==Evaluation=="

← Older revision		Revision as of 01:57, 28 July 2016
Line 22:		Line 22:
	{{Fever in Traveler DDX}}		{{Fever in Traveler DDX}}

	==~~Diagnostic~~ Evaluation==		==Evaluation==
	*Confirm by serology		*Confirm by serology
	*Culture		*Culture

Neil.m.young: Text replacement - " ==" to "=="

2016-07-06T04:44:58Z

Text replacement - " ==" to "=="

← Older revision		Revision as of 04:44, 6 July 2016
Line 31:		Line 31:
	*CSF with elevated wbcs and protein with normal glucose		*CSF with elevated wbcs and protein with normal glucose

	==Management<ref>http://www.moh.gov.my/images/gallery/Garispanduan/GL_Leptospirosis%202011.pdf Ministry of Health Malaysia 2011 Recommendations</ref> ==		==Management<ref>http://www.moh.gov.my/images/gallery/Garispanduan/GL_Leptospirosis%202011.pdf Ministry of Health Malaysia 2011 Recommendations</ref>==
	*Penicillin G 100000U/ kg/ dose IV every 6 hours x 7days		*Penicillin G 100000U/ kg/ dose IV every 6 hours x 7days
	'''OR'''		'''OR'''

Ostermayer: Text replacement - " pts" to " patients"

2016-06-21T16:49:43Z

Text replacement - " pts" to " patients"

← Older revision		Revision as of 16:49, 21 June 2016
Line 12:		Line 12:
	==Clinical Features==		==Clinical Features==
	*Acute phase (lasts up to 1 week)		*Acute phase (lasts up to 1 week)
	**Mild illness to abrupt high fever, chills, intense headache, and severe myalgias (75-100% of ~~pts~~)		**Mild illness to abrupt high fever, chills, intense headache, and severe myalgias (75-100% of patients)
	*Conjunctival suffusion (redness without exudates) characteristic but not common		*Conjunctival suffusion (redness without exudates) characteristic but not common
	*Meningitis, uveitis, transaminitis, hepatomegaly, proteinuria, hematuria		*Meningitis, uveitis, transaminitis, hepatomegaly, proteinuria, hematuria

Kian: epidemiology

2016-05-19T12:40:09Z

epidemiology

← Older revision		Revision as of 12:40, 19 May 2016
Line 5:		Line 5:
	*Average incubation of 10 days		*Average incubation of 10 days
	*Also described following hiking, trekking, and following triathlon competitions<ref>CDC. Update: leptospirosis and unexplained acute febrile illness among athletes participating in triathlons--Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep. 1998;47(32):673-6</ref>		*Also described following hiking, trekking, and following triathlon competitions<ref>CDC. Update: leptospirosis and unexplained acute febrile illness among athletes participating in triathlons--Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep. 1998;47(32):673-6</ref>
			*Global estimate 1 million cases annually, 58,900 deaths<ref>Costa, F., Hagan, J.E., Calcagno, J., Kane, M., Torgerson, P., Martinez-Silveira, M.S., Stein, C., Abela-Ridder, B. and Ko, A.I. (2015) ‘Global morbidity and mortality of Leptospirosis: A systematic review’, PLOS Neglected Tropical Diseases, 9(9),</ref>
	*Uncommon in the US, although 50% of cases dx in Hawaii		*Uncommon in the US, although 50% of cases dx in Hawaii

Kian: background

2016-05-19T12:35:53Z

background

← Older revision		Revision as of 12:35, 19 May 2016
Line 5:		Line 5:
	*Average incubation of 10 days		*Average incubation of 10 days
	*Also described following hiking, trekking, and following triathlon competitions<ref>CDC. Update: leptospirosis and unexplained acute febrile illness among athletes participating in triathlons--Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep. 1998;47(32):673-6</ref>		*Also described following hiking, trekking, and following triathlon competitions<ref>CDC. Update: leptospirosis and unexplained acute febrile illness among athletes participating in triathlons--Illinois and Wisconsin, 1998. MMWR Morb Mortal Wkly Rep. 1998;47(32):673-6</ref>
			*Uncommon in the US, although 50% of cases dx in Hawaii

	[[File:Conjunctivalsuffusion.jpg\|thumb\|Conjunctival suffusion]]		[[File:Conjunctivalsuffusion.jpg\|thumb\|Conjunctival suffusion]]